Japan Biotechno Pharma was founded in August 2016 for brighter future of patients and families.
Our ambition is to contribute for society and healthcare through useful antibody technology.
The cost of social security continues to rise in Japan.
In particular, with the graying of society, the increase in the population requiring nursing care and the sophistication of medical technology, healthcare costs and economic loads are expected to heavily burden not only the working generation but the next generation as well.
What can we do?
How can we help save as many patients - and their families - as possible?
These were our thoughts behind the founding of this company.
I was involved in the pharmaceutical industry for 28 years at a foreign-affiliated pharmaceutical company before establishing this company.
I am committed to giving my utmost to be of service to healthcare and society in japan.
We have faith in the outcome of our dream and convictions.
It would be great if you could look forward to seeing what we achieve.
Naoki Shinohara, CEO
Japan Biotechno Pharma engages in its business activities with the aim of contributing to the creation of a richer social environment and the realization of brighter future for patients and their families through beneficial antibody technology.
No current openings